A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (TAR-210)
Last Updated September 4, 2024
Want to learn how to participate in this trial?
CR109248
OVERVIEW
-
Gender
all -
Age
years -
Phase
phase 11 -
Sites
Sites -
Status
Recruiting
SUMMARY
CONDITIONS
- Bladder Cancer
- Receptors, Fibroblast Growth Factor
ELIGIBILITY
Inclusion Criteria:
* Histologically confirmed non-muscle-invasive urothelial carcinoma of the bladder
* All visible tumors must be completely resected prior to the start of study treatment and documented on screening cystoscopy
* Confirmed recurrence of non-muscle invasive bl
DETAILS
LOCATIONS
Country (1) | City or Province (4) | Status |
Japan | Kanagawa St Marianna University Hospital |
RECRUITING
|
Japan | Osaka City Osaka International Cancer Institute |
RECRUITING
|
Japan | Toyama-shi Toyama University Hospital |
RECRUITING
|
Japan | Tsukuba University of Tsukuba Hospital |
RECRUITING
|
37.58333, 139.91667
34.69374, 135.50218
36.7, 137.21667
36.2, 140.1
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.